A phase 2b/3, multi-center, observer-blind, controlled study of the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine administered to healthy adolescents aged 11-17 years according to different vaccination schedules.

Trial Profile

A phase 2b/3, multi-center, observer-blind, controlled study of the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine administered to healthy adolescents aged 11-17 years according to different vaccination schedules.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Meningococcal vaccine group B (Primary)
  • Indications Meningococcal group B infections; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 23 Apr 2012 Actual end date for the extension trial (NCT01148524) is now Jan 2012.
    • 23 Apr 2012 Actual end date for the extension trial (NCT01148524) is now Jan 2012.
    • 23 Apr 2012 Status of the extension trial (NCT01148524) changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top